De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2-and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET

被引:109
作者
Harbeck, Nadia [1 ,4 ]
Gluz, Oleg [4 ,5 ]
Christgen, Matthias [6 ]
Kates, Ronald Ernest [4 ]
Braun, Michael [2 ]
Kueemmel, Sherko [7 ]
Schumacher, Claudia [9 ]
Potenberg, Jochem [11 ]
Kraemer, Stefan [10 ]
Kleine-Tebbe, Anke [12 ]
Augustin, Doris [13 ]
Aktas, Bahriye [8 ]
Forstbauer, Helmut [14 ]
Tio, Joke [15 ]
von Schumann, Raquel [5 ]
Liedtke, Cornelia [16 ]
Grischke, Eva-Maria [17 ]
Schumacher, Johannes [18 ]
Wuerstlein, Rachel [3 ,4 ]
Kreipe, Hans Heinrich [6 ]
Nitz, Ulrike Anneliese [4 ,5 ]
机构
[1] Ludwig Maximilians Univ Hosp Munich, Munich, Germany
[2] Red Cross Hosp Munich, Munich, Germany
[3] Univ Hosp Munich, Munich, Germany
[4] West German Study Grp, Monchengladbach, Germany
[5] Evangel Hosp Bethesda, Monchengladbach, Germany
[6] Hannover Med Sch, Hannover, Germany
[7] Kliniken Essen Mitte, Essen, Germany
[8] Essen Univ Hosp, Essen, Germany
[9] St Elizabeth Hosp, Cologne, Germany
[10] Univ Clin, Cologne, Germany
[11] Evangel Waldkrankenhaus, Berlin, Germany
[12] DRK Kliniken, Berlin, Germany
[13] Clin Deggendorf, Deggendorf, Germany
[14] Onkol Rheinsieg, Troisdorf, Germany
[15] Univ Hosp Munster, Munster, Germany
[16] Univ Lubeck, Lubeck, Germany
[17] Univ Hosp Tubingen, Tubingen, Germany
[18] Palleos Healthcare Serv, Wiesbaden, Germany
关键词
CHEMOTHERAPY; PERTUZUMAB; MULTICENTER; DOCETAXEL;
D O I
10.1200/JCO.2016.71.9815
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Human epidermal growth factor receptor 2 (HER2)-positive/hormone receptor (HR)-positive breast cancer is a distinct subgroup associatedwith lower chemotherapy sensitivity and slightly better outcome than HER2-positive/HR-negative disease. Little is known about the efficacy of the combination of endocrine therapy (ET) with trastuzumab or with the potent antibody-cytotoxic, anti-HER2 compound trastuzumab emtansine (T-DM1) with or without ET for this subgroup. The West German Study Group trial, ADAPT (Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer) compares pathologic complete response (pCR) rates of T-DM1 versus trastuzumab with ET in early HER2-positive/HR-positive breast cancer. Patients and Methods In this prospective, neoadjuvant, phase II trial, 375 patients with early breast cancer with HER2positive and HR-positive status (n = 463 screened) were randomly assigned to 12 weeks of T-DM1 with or without ET or to trastuzumab with ET. The primary end point was pCR (ypT0/is/ypN0). Early response was assessed in 3-week post-therapeutic core biopsies (proliferation decrease $ 30% Ki-67 or cellularity response). Secondary end points included safety and predictive impact of early response on pCR. Adjuvant therapy followed national standards. Results Baseline characteristics were well balanced among the arms. More than 90% of patients completed the therapy per protocol. pCR was observed in 41.0% of patients treated with T-DM1, 41.5% of patients treated with T-DM1 and ET, and 15.1% with trastuzumab and ET (P<.001). Early responders (67% of patients with assessable response) achieved pCR in 35.7% compared with 19.8% in nonresponders (odds ratio, 2.2; 95% CI, 1.24 to 4.19). T-DM1 was associated with a significantly higher prevalence of grade 1 to 2 toxicities, especially thrombocytopenia, nausea, and elevation of liver enzymes. Overall toxicity was low; seventeen therapy-related severe adverse events (T-DM1 arms v trastuzumab plus ET; 5.3% v 3.1%, respectively) were reported. Conclusion The ADAPT HER2-positive/HR-positive trial demonstrates that neoadjuvant T-DM1 (with or without ET) given for only 12 weeks results in a clinically meaningful pCR rate. Thus, a substantial number of patients are spared the adverse effects of systemic chemotherapy. (C) 2017 by American Society of Clinical Oncology
引用
收藏
页码:3046 / +
页数:11
相关论文
共 23 条
[1]   PAM50 intrinsic subtype as a predictor of pathological complete response following neoadjuvant dual HER2 blockade without chemotherapy in HER2-positive breast cancer: First results of the PAMELA clinical trial [J].
Aparicio, A. Prat ;
Castan, J. Cortes ;
Pare, L. ;
Galvan, P. ;
Bermejo, B. ;
Martinez, N. ;
Vidal, M. ;
Pernas, S. ;
Lopez, R. ;
Munoz, M. ;
Nuciforo, P. ;
Fasani, R. ;
Morales, S. ;
Oliveira, M. ;
de la Pena, L. ;
Pelaez, A. ;
Llombart, A. .
CANCER RESEARCH, 2017, 77
[2]   Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes A Meta-Analysis [J].
Broglio, Kristine R. ;
Quintana, Melanie ;
Foster, Margaret ;
Olinger, Melissa ;
McGlothlin, Anna ;
Berry, Scott M. ;
Boileau, Jean-Francois ;
Brezden-Masley, Christine ;
Chia, Stephen ;
Dent, Susan ;
Gelmon, Karen ;
Paterson, Alexander ;
Rayson, Daniel ;
Berry, Donald A. .
JAMA ONCOLOGY, 2016, 2 (06) :751-760
[3]   Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J].
Cortazar, Patricia ;
Zhang, Lijun ;
Untch, Michael ;
Mehta, Keyur ;
Costantino, Joseph P. ;
Wolmark, Norman ;
Bonnefoi, Herve ;
Cameron, David ;
Gianni, Luca ;
Valagussa, Pinuccia ;
Swain, Sandra M. ;
Prowell, Tatiana ;
Loibl, Sibylle ;
Wickerham, D. Lawrence ;
Bogaerts, Jan ;
Baselga, Jose ;
Perou, Charles ;
Blumenthal, Gideon ;
Blohmer, Jens ;
Mamounas, Eleftherios P. ;
Bergh, Jonas ;
Semiglazov, Vladimir ;
Justice, Robert ;
Eidtmann, Holger ;
Paik, Soonmyung ;
Piccart, Martine ;
Sridhara, Rajeshwari ;
Fasching, Peter A. ;
Slaets, Leen ;
Tang, Shenghui ;
Gerber, Bernd ;
Geyer, Charles E., Jr. ;
Pazdur, Richard ;
Ditsch, Nina ;
Rastogi, Priya ;
Eiermann, Wolfgang ;
von Minckwitz, Gunter .
LANCET, 2014, 384 (9938) :164-172
[4]   Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer [J].
Dowsett, Mitch ;
Smith, Ian E. ;
Ebbs, Stephen R. ;
Dixon, J. Michael ;
Skene, Anthony ;
A'Hern, Roger ;
Salter, Janine ;
Detre, Simone ;
Hills, Margaret ;
Walsh, Geraldine .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (02) :167-170
[5]   Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance) [J].
Ellis, Matthew J. ;
Suman, Vera J. ;
Hoog, Jeremy ;
Goncalves, Rodrigo ;
Sanati, Souzan ;
Creighton, Chad J. ;
DeSchryver, Katherine ;
Crouch, Erika ;
Brink, Amy ;
Watson, Mark ;
Luo, Jingqin ;
Tao, Yu ;
Barnes, Michael ;
Dowsett, Mitchell ;
Budd, G. Thomas ;
Winer, Eric ;
Silverman, Paula ;
Esserman, Laura ;
Carey, Lisa ;
Ma, Cynthia X. ;
Unzeitig, Gary ;
Pluard, Timothy ;
Whitworth, Pat ;
Babiera, Gildy ;
Guenther, J. Michael ;
Dayao, Zoneddy ;
Ota, David ;
Leitch, Marilyn ;
Olson, John A., Jr. ;
Allred, D. Craig ;
Hunt, Kelly .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (10) :1061-+
[6]   5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial [J].
Gianni, Luca ;
Pienkowski, Tadeusz ;
Im, Young-Hyuck ;
Tseng, Ling-Ming ;
Liu, Mei-Ching ;
Lluch, Ana ;
Staroslawska, Elzbieta ;
de la Haba-Rodriguez, Juan ;
Im, Seock-Ah ;
Pedrini, Jose Luiz ;
Poirier, Brigitte ;
Morandi, Paolo ;
Semiglazov, Vladimir ;
Srimuninnimit, Vichien ;
Bianchi, Giulia Valeria ;
Magazzu, Domenico ;
McNally, Virginia ;
Douthwaite, Hannah ;
Ross, Graham ;
Valagussa, Pinuccia .
LANCET ONCOLOGY, 2016, 17 (06) :791-800
[7]  
Harbeck N, 2015, J CLIN ONCOL S, V33
[8]   WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial [J].
Hofmann, Daniel ;
Nitz, Ulrike ;
Gluz, Oleg ;
Kates, Ronald E. ;
Schinkoethe, Timo ;
Staib, Peter ;
Harbeck, Nadia .
TRIALS, 2013, 14
[9]   Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer [J].
Hurvitz, Sara A. ;
Dirix, Luc ;
Kocsis, Judit ;
Bianchi, Giulia V. ;
Lu, Janice ;
Vinholes, Jeferson ;
Guardino, Ellie ;
Song, Chunyan ;
Tong, Barbara ;
Ng, Vivian ;
Chu, Yu-Waye ;
Perez, Edith A. .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (09) :1157-1163
[10]   HERMIONE: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1). [J].
Miller, Kathy ;
Cortes, Javier ;
Hurvitz, Sara A. ;
Krop, Ian E. ;
Tripathy, Debu ;
Verma, Sunil ;
Dionne, Michelle ;
Campbell, Karen ;
Reynolds, Joseph G. ;
Wickham, Thomas J. ;
Molnar, Istvan ;
Yardley, Denise A. .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)